Results 41 to 50 of about 286,157 (290)
PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib
Frontiers in Oncology, 2021 Multiple myeloma (MM), the second most commonly diagnosed hematologic neoplasm, is the most significant clinical manifestation in a series of plasma cell (PC) dyscrasia.
Dong Wu +8 more
doaj +1 more source
Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
Frontiers in Oncology, 2019 Tumor plasticity refers to tumor cell's inherent property of transforming one type of cell to different types of cells. Tumor plasticity is the main cause of tumor relapse, metastasis and drug resistance.
Xiao-Guang Yang +4 more
doaj +1 more source
Indian Journal of Pathology and Microbiology, 2013 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the ...
Mukul Vij, Susama Patra, Mohamed Rela
doaj +1 more source
Idiopathic noncirrhotic portal hypertension: current perspectives [PDF]
, 2016 The term idiopathic noncirrhotic portal hypertension (INCPH) has been recently proposed to replace terms, such as hepatoportal sclerosis, idiopathic portal hypertension, incomplete septal cirrhosis, and nodular regenerative hyperplasia, used to describe ...
D'AMATI, Giulia +5 more
core +1 more source
Transcutaneous electrical nerve stimulation for cancer pain in adults. [PDF]
, 2008 Background Cancer-related pain is complex and multi-dimensional but the mainstay of cancer pain management has predominately used a biomedical approach. There is a need for non-pharmacological and innovative approaches.
Bennett, Michael I. +4 more
core +1 more source
Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. [PDF]
, 2020 Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/
Barkauskas, Donald A +4 more
core +1 more source
Frontiers in Oncology, 2023 Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are ...
Antoine Domenger +6 more
doaj +1 more source
DACH1 suppresses breast cancer as a negative regulator of CD44. [PDF]
, 2017 Dachshund homolog 1 (DACH1), a key cell fate determination factor, contributes to tumorigenesis, invasion, metastasis of human breast neoplasm. However, the exact molecular mechanisms for the anti-tumor roles of DACH1 in breast carcinoma are still lack ...
Kuang, Dong +6 more
core +2 more sources
Imatinib-induced interstitial pneumonitis – a literature review and case report [PDF]
, 2020 Imatinib is generally well tolerated, with mild common side effects such as nausea and vomiting, diarrhea, muscle cramps, fatigue, skin rash and edema; however, pulmonary complications are uncommon. A 73-year-old woman undergoing one month treatment with
Ciulei, George +12 more
core +2 more sources
Clinical Insights Into Hypercalcemia of Malignancy in Childhood
Pediatric Blood &Cancer, EarlyView.ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley +1 more source